Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed ...

On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) ...

Shares of Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) have received an average recommendation of Hold from the sixteen research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold...

Elliott Levy, M.D. Editas Medicine announced the appointment of Elliott Levy, M.D., to its Board of Directors as an independent director. Emma Reeve Editas Medicine today announced the appointment of current Independent Director Emma Reeve as Chair of the Board. Emma Reeve to support Editas ...

Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Companys ...